Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Subscribe To Our Newsletter & Stay Updated